New hope for bleeding risk: drug boosts platelets in hepatitis b patients
NCT ID NCT03664518
First seen Feb 14, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tested a drug called eltrombopag in 48 adults with chronic hepatitis B who also had a low platelet count (immune thrombocytopenia). The goal was to see if taking the drug for 6 weeks could safely raise platelet levels to reduce bleeding risk. Results focused on how many patients reached a safe platelet count by day 43.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.